Truist Financial
ANIK icon

Truist Financial’s Anika Therapeutics ANIK Stock Holding History

Truist Financial’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,882
Closed -$946K – 2622
2020
Q4 		$946K Buy
20,882
+93
+0.4% +$3.53K ﹤0.01% 1508
2020
Q3 		$737K Buy
20,789
+2,104
+11% +$76K ﹤0.01% 1512
2020
Q2 		$705K Sell
18,685
-1,738
-9% -$57.3K ﹤0.01% 1442
2020
Q1 		$590K Buy
20,423
+4,139
+25% +$167K ﹤0.01% 1495
2019
Q4 		$844K Buy
+16,284
New +$946K ﹤0.01% 1530

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Truist Financial's ANIK Position: Q1 2021 in Review

Truist Financial sold out of Anika Therapeutics (ANIK) in Q1 2021, closing a stake of 20,882 shares — an estimated $946K sold.

Truist Financial first reported a position in ANIK in Q4 2019 and held it in 5 quarters. The position peaked at $946K in Q4 2020. 145 funds tracked by Wall St. Rank hold ANIK as of Q1 2021.

  • Truist Financial reported no remaining Anika Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Truist Financial sold 20,882 Anika Therapeutics shares in Q1 2021, an estimated $946K.
  • Truist Financial first reported a position in Anika Therapeutics in Q4 2019 and held it in 5 quarters.
  • Truist Financial's Anika Therapeutics position peaked at $946K in Q4 2020.
  • 145 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2021.

Based on Truist Financial's 13F filing for Q1 2021, filed 17 May 2021.